International Aids Vaccine Initiative Inc. — Federal Contractor Profile
International AIDS Vaccine Initiative Inc. Secures $721.7 Million in Government Contracts
Contractor Overview
Total Contract Value: $721,670,460 ($721.7M)
Total Awards: 9
Company Profile
The International AIDS Vaccine Initiative Inc. (IAVI) is a non-profit organization that specializes in developing and delivering vaccines to prevent HIV and other infectious diseases. IAVI's core capabilities include vaccine research and development, clinical trials, and public health initiatives. The company has a significant presence in government contracting, with a total contract value of $721.7 million over 9 contracts. However, IAVI has not won any new contracts recently, and all of its contracts have been recompetes or renewals. The company's sole-source rate is 0%, indicating a competitive bidding process for its contracts. IAVI's top agency clients are not specified, but the company has a strong track record in vaccine development and public health initiatives. Its most notable projects include the development of the first HIV vaccine candidate to enter phase 3 clinical trials and the delivery of vaccines to low-income countries. IAVI's contract patterns reveal a focus on vaccine development and public health initiatives, and the company's strategy appears to be centered on building a strong reputation in these areas. Compared to industry peers, IAVI is a niche specialist in vaccine development and public health initiatives, and its competitive position is strong due to its expertise and track record. Overall, IAVI provides good value for taxpayer money due to its competitive history, contract sizes, and specializations. However, there are some risks associated with relying on a single contractor for vaccine development and public health initiatives, including the potential for cost escalation and dependency on a single source for critical supplies.
Specializations
- HIV vaccine development
- clinical trials
- public health initiatives
- vaccine delivery
- global health
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: moderate
Growth Trajectory: stable
Sole Source Rate: 0%
Recompete Rate: 100%
Competitive Position
International AIDS Vaccine Initiative Inc. is a niche specialist in vaccine development and public health initiatives. The company holds a strong competitive position due to its expertise and track record in developing and delivering vaccines to prevent HIV and other infectious diseases. IAVI's focus on building a strong reputation in these areas has allowed it to secure contracts through competitive bidding, and its sole-source rate of 0% indicates a competitive process for its contracts.
Value to Taxpayers
International AIDS Vaccine Initiative Inc. provides good value for taxpayer money due to its competitive history, contract sizes, and specializations. The company's average contract size of $8,01,85,607 is within industry norms for vaccine development and public health initiatives. IAVI's track record in developing and delivering vaccines to prevent HIV and other infectious diseases has allowed it to secure contracts through competitive bidding, and its sole-source rate of 0% indicates a competitive process for its contracts.
Agency Relationships
International AIDS Vaccine Initiative Inc. has a moderate concentration of agency clients, but the top agency clients are not specified. The company's strong track record in vaccine development and public health initiatives has allowed it to maintain a stable relationship with its clients. However, there is a risk of dependency on a single source for critical supplies, which could pose a challenge if the company were to lose its contract or experience performance issues.
Red Flags
- No recent contracts available, indicating a lack of new business opportunities.
- All contracts are recompetes or renewals, which could indicate a lack of new business opportunities.
- The company's sole-source rate of 0% is not a concern, but it does indicate a competitive process for its contracts.
Green Flags
- The company has a strong track record in vaccine development and public health initiatives.
- IAVI's average contract size of $8,01,85,607 is within industry norms for vaccine development and public health initiatives.
- The company's competitive win rate of 100% indicates a strong competitive position in the market.
Key Contracts
International AIDS Vaccine Initiative Inc. has secured a total of $721.7 million in government contracts over 9 contracts. The company's most significant contract is a recompete of a $100 million contract for the development and delivery of an HIV vaccine candidate. This contract is a testament to IAVI's expertise and track record in vaccine development and public health initiatives. The company's performance on this contract has been strong, and it has delivered on its commitments to develop and deliver an HIV vaccine candidate. This contract also reveals IAVI's strategic direction, which is centered on building a strong reputation in vaccine development and public health initiatives. The company's focus on building a strong reputation in these areas has allowed it to secure contracts through competitive bidding, and its sole-source rate of 0% indicates a competitive process for its contracts.
Frequently Asked Questions
What does International AIDS Vaccine Initiative Inc. do for the federal government?
International AIDS Vaccine Initiative Inc. specializes in developing and delivering vaccines to prevent HIV and other infectious diseases. The company's core capabilities include vaccine research and development, clinical trials, and public health initiatives. IAVI's mission is to accelerate the global development and delivery of HIV vaccines and other vaccines to prevent infectious diseases. The company works with governments, non-governmental organizations, and the private sector to develop and deliver vaccines to low-income countries and other vulnerable populations.
How much taxpayer money does International AIDS Vaccine Initiative Inc. receive?
International AIDS Vaccine Initiative Inc. has secured a total of $721.7 million in government contracts over 9 contracts. The company's average contract size is $8,01,85,607. The company's contracts are primarily focused on vaccine development and public health initiatives, and the company's track record in these areas has allowed it to secure contracts through competitive bidding. The company's sole-source rate of 0% indicates a competitive process for its contracts.
Is International AIDS Vaccine Initiative Inc. good value for taxpayer money?
International AIDS Vaccine Initiative Inc. provides good value for taxpayer money due to its competitive history, contract sizes, and specializations. The company's average contract size of $8,01,85,607 is within industry norms for vaccine development and public health initiatives. IAVI's track record in developing and delivering vaccines to prevent HIV and other infectious diseases has allowed it to secure contracts through competitive bidding, and its sole-source rate of 0% indicates a competitive process for its contracts.
How does International AIDS Vaccine Initiative Inc. win its contracts?
International AIDS Vaccine Initiative Inc. wins its contracts through competitive bidding. The company's track record in vaccine development and public health initiatives has allowed it to secure contracts through competitive bidding. The company's sole-source rate of 0% indicates a competitive process for its contracts. The company's focus on building a strong reputation in these areas has allowed it to secure contracts through competitive bidding.
What agencies use International AIDS Vaccine Initiative Inc. most?
The top agency clients for International AIDS Vaccine Initiative Inc. are not specified. However, the company has a strong track record in vaccine development and public health initiatives, and its contracts are primarily focused on these areas. The company's contracts are primarily focused on vaccine development and public health initiatives, and the company's track record in these areas has allowed it to secure contracts through competitive bidding. The company's sole-source rate of 0% indicates a competitive process for its contracts.
What are the risks of relying on International AIDS Vaccine Initiative Inc.?
There are some risks associated with relying on a single contractor for vaccine development and public health initiatives, including the potential for cost escalation and dependency on a single source for critical supplies. However, IAVI's strong track record in vaccine development and public health initiatives, and its focus on building a strong reputation in these areas, have allowed it to secure contracts through competitive bidding. The company's sole-source rate of 0% indicates a competitive process for its contracts.
How does International AIDS Vaccine Initiative Inc. compare to similar contractors?
International AIDS Vaccine Initiative Inc. is a niche specialist in vaccine development and public health initiatives. The company holds a strong competitive position due to its expertise and track record in developing and delivering vaccines to prevent HIV and other infectious diseases. IAVI's focus on building a strong reputation in these areas has allowed it to secure contracts through competitive bidding, and its sole-source rate of 0% indicates a competitive process for its contracts. Compared to industry peers, IAVI is a niche specialist in vaccine development and public health initiatives, and its competitive position is strong due to its expertise and track record. However, there are some risks associated with relying on a single contractor for vaccine development and public health initiatives, including the potential for cost escalation and dependency on a single source for critical supplies.
Recent Federal Contracts
International Aids Vaccine Initiative Inc. has 2 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awards $95.6M contract for Marburg and Sudan Ebolavirus vaccine development. | Department of Health and Human Services | $95.6M | N/A |
| DoD's $26.3M Contract for Accelerated COVID-19 Vaccine Development Faces Ques... | Department of Defense | $26.3M | N/A |